降浊化瘀合剂对2型糖尿病合并非酒精性脂肪肝大鼠的肝脏保护作用

Protective effect of descending turbidity and removing blood stasis decoction to the type 2 diabetes combined with non alcoholic fatty liver rat

目的:观察降浊化瘀合剂对2型糖尿病(T2DM)合并非酒精性脂肪肝(NAFLD)大鼠的肝脏保护作用。方法:建立T2DM合并NAFLD大鼠模型并随机分为中药组、对照组和模型组,分别给予降浊化瘀合剂、马来酸罗格列酮片和蒸馏水灌胃并与正常组对照。给药8周后检测血清谷丙转氨酶(ALT)、谷草转氨酶(AST)、肝指数、肝组织谷胱甘肽(GSH)、丙二醛(MDA)、超氧化物歧化酶(SOD)水平及肝脏病理学变化。结果:中药组肝脏脂肪变性程度明显减轻,中药组血清ALT水平明显低于模型ameliorate组(P<0.01),中药组肝匀浆中SOD、GSH较模型组显著升高,而MDA含量降低(P均<0.01)。结论:降浊化瘀合剂可改善T2DM合并NAFLD大鼠肝组织脂肪变性程度,降低血清转氨酶,提高肝组织抗氧化能力。

Objective： To observe the Jiangzhuo Huayu Mixture （JZHYM）＇s influence on rats with type 2 diabetes （T2DM） combined nonalcoholic fatty liver disease （NAFLD）. Method： The rat models of T2DM with NAFLD were established, after validation, the successfully established model rats were randomly divided into Chinese medicine group （JZHYM treatment）, western medicine group （Rosiglitazone Maleate treatment）, and the model group （garaged with disilled water）. After dosing 8 weeks, fiver pathology changes, liver index, ALT, AST, liver tissue homogenate superoxide dismutase （SOD） vigor, malondialdehyde （MDA） and glutathione （GSH） were detected respectively. Results： JZHYM can significantly ameliorate model rats＇ liver steatosis, lower serum ALT （P 〈 0. 01 ）. Liver homogenate SOD and GSH in Chinese medicine group were higher than those in model group（ P 〈 0.01 ） , while MDA content reduced significantly （P 〈 0.01）. Conclusion： JZHYM can protect liver function obviously, ameliorate liver tissue steatosis, reduce serum trausaminase level and improve liver tissue＇ s antioxidant capacity.